Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6	7.56	6.07	9.29	13.52	15.19
Short-Term Investments	0.69	2.8	8.2	10.49	26.37	45.98
Cash & Short-Term Investments	6.69	10.37	14.27	19.78	39.89	61.16
Cash Growth	-28.60%	-27.34%	-27.89%	-50.41%	-34.77%	422.83%
Other Receivables	3.27	0.2	0.26	0.29	0.46	0.18
Receivables	3.27	0.2	0.26	0.29	0.46	0.18
Prepaid Expenses	-	2.86	1.44	0.75	1.31	1.35
Restricted Cash	-	-	0.08	0.08	0.08	-
Total Current Assets	9.96	13.43	16.04	20.9	41.74	62.69
Property, Plant & Equipment	0.16	0.18	0.54	0.7	0.59	0.7
Other Long-Term Assets	0.12	0.21	0.39	0.56	0.73	0.96
Total Assets	10.24	13.81	16.96	22.15	43.06	64.35

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.26	0.49	0.63	0.52	1.69	1.34
Accrued Expenses	1.3	0.99	2.47	4.25	4.94	1.21
Current Portion of Leases	-	-	0.12	0.08	0.12	0.11
Total Current Liabilities	1.55	1.48	3.22	4.84	6.75	2.65
Long-Term Leases	-	-	0.21	0.32	0.09	0.24
Total Liabilities	1.55	1.48	3.43	5.15	6.84	2.89

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Additional Paid-In Capital	124.24	123.95	116.16	105.68	101.26	97.64
Retained Earnings	-115.56	-111.62	-102.62	-88.68	-63.82	-36.17
Treasury Stock	-	-	-	-	-1.22	-
Total Common Equity	8.69	12.33	13.54	17	36.22	61.47
Shareholders' Equity	8.69	12.33	13.54	17	36.22	61.47
Total Liabilities & Equity	10.24	13.81	16.96	22.15	43.06	64.35

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	-	-	0.32	0.39	0.21	0.34
Net Cash (Debt)	6.69	10.37	13.94	19.39	39.68	60.82
Net Cash Growth	-28.60%	-25.65%	-28.10%	-51.13%	-34.76%	439.64%
Net Cash Per Share	0.89	1.63	3.11	6.60	13.95	23.45
Filing Date Shares Outstanding	7.25	7.19	4.71	3.55	2.76	2.85
Total Common Shares Outstanding	7.25	7.19	4.71	3.55	2.76	2.85
Working Capital	8.4	11.95	12.82	16.06	34.99	60.04
Book Value Per Share	1.20	1.71	2.87	4.79	13.11	21.56
Tangible Book Value	8.69	12.33	13.54	17	36.22	61.47
Tangible Book Value Per Share	1.20	1.71	2.87	4.79	13.11	21.56
Machinery	-	0.47	0.5	0.5	0.5	0.43
Leasehold Improvements	-	-	0.01	0.01	0.02	0.02

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 19, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 29, 2026

Data Sources Report a data error